Technical Analysis for XRTX - XORTX Therapeutics Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 2.55 | -1.87% | -0.05 |
XRTX closed up 1.45 percent on Thursday, May 2, 2024, on 7 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 15
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Narrow Range Bar | Range Contraction | -1.87% | |
Wide Bands | Range Expansion | -1.87% | |
Oversold Stochastic | Weakness | -1.87% | |
NR7 | Range Contraction | -0.45% | |
Narrow Range Bar | Range Contraction | -0.45% | |
Wide Bands | Range Expansion | -0.45% | |
Oversold Stochastic | Weakness | -0.45% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
20 DMA Resistance | Bearish | -3.59% |
Alert | Time |
---|---|
Down 1% | 27 minutes ago |
Rose Above Previous Day's High | 1 day ago |
Outside Day | 1 day ago |
Up 5% | 1 day ago |
Up 3% | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/15/2024
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.
Sector: Technology
Industry: Data Storage
Keywords: Pharmaceutical Organ Systems Infection Kidney Disease Kidney Diabetic Nephropathy Autosomal Dominant Polycystic Kidney Disease
Classification
Sector: Technology
Industry: Data Storage
Keywords: Pharmaceutical Organ Systems Infection Kidney Disease Kidney Diabetic Nephropathy Autosomal Dominant Polycystic Kidney Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 67.7079 |
52 Week Low | 1.98 |
Average Volume | 57,619 |
200-Day Moving Average | 19.77 |
50-Day Moving Average | 3.67 |
20-Day Moving Average | 3.10 |
10-Day Moving Average | 2.77 |
Average True Range | 0.34 |
RSI (14) | 37.50 |
ADX | 27.56 |
+DI | 16.23 |
-DI | 26.01 |
Chandelier Exit (Long, 3 ATRs) | 2.90 |
Chandelier Exit (Short, 3 ATRs) | 3.53 |
Upper Bollinger Bands | 3.93 |
Lower Bollinger Band | 2.28 |
Percent B (%b) | 0.19 |
BandWidth | 53.15 |
MACD Line | -0.31 |
MACD Signal Line | -0.27 |
MACD Histogram | -0.0401 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.78 | ||||
Resistance 3 (R3) | 2.77 | 2.71 | 2.75 | ||
Resistance 2 (R2) | 2.71 | 2.66 | 2.71 | 2.74 | |
Resistance 1 (R1) | 2.65 | 2.63 | 2.68 | 2.66 | 2.73 |
Pivot Point | 2.59 | 2.59 | 2.60 | 2.59 | 2.59 |
Support 1 (S1) | 2.53 | 2.54 | 2.56 | 2.54 | 2.47 |
Support 2 (S2) | 2.47 | 2.51 | 2.47 | 2.46 | |
Support 3 (S3) | 2.41 | 2.47 | 2.45 | ||
Support 4 (S4) | 2.42 |